Mode
Text Size
Log in / Sign up
N/A N=29

Role of the Gut Microbiome on Lean Mass and Physical Function in Older Adults

Sarcopenia

Enrolled (actual)
29
Serious AEs
0.0%
Results posted
Aug 2020
Primary outcome: Primary: Percentage of Whole Body Lean Mass (%WBLM) — 67.3; 61.9 % of whole body mass

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Age
Older Adult · 70+ yrs
Sex
All
Sponsor
Tufts University
Primary completion
Feb 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Whole Body Lean Mass (%WBLM)
67.3; 61.9
PRIMARY
Physical Function Measurement
11.2; 7.4
PRIMARY
400-meter Gait Speed
1.12; 0.96
PRIMARY
Leg Press 1 Repetition Maximum
1863.9; 1343.2

Summary

The investigators recently published significant associations between circulating gut bacteria-related metabolites with lean and skeletal muscle mass and with measures of physical function in older adults, evidence that suggests a role for gut bacteria on the maintenance of these outcomes. To date, studies aimed at identification of associations between gut bacteria with lean mass or with specific measures of physical function have yet to be reported. Accordingly, the over-arching hypothesis is that gut bacteria are associated with, and are causatively involved in mechanisms that underlie the maintenance of lean mass and physical function in older adults. Results obtained from the proposed study are intended as the basis for future studies aimed at targeted modulation of the gut microflora, which may be a novel and innovative means for improving lean mass and physical function, and for addressing the public health priority of healthy aging in older adults.

Eligibility Criteria

Inclusion Criteria

i) Willing and able to sign the IRB approved informed consent form ii) Male and Female iii) 70-85 years of age iv) BMI ≤ 35 kg/m2 v) Willing to come to the HNRCA laboratory for baseline and 1-month follow-up study visits vi) SPPB ≥ 11 ("High-Functioning", HF; 20 subjects: 10 males, 10 females) vii) 4 ≤ SPPB ≤ 7 ("Low-Functioning", LF; 20 subjects: 10 males, 10 females)

Exclusion Criteria

i) Non-English speaker ii) Acute or terminal illness iii) Surgery in the past 6 months iv) Lower extremity fracture within the past 6 months v) Myocardial infarction in the past 6 months vi) Coronary artery disease, peripheral vascular disease, previous stroke, or history of transient ischemic attacks vii) Cognitive impairment (MMSE score 160/100 mmHg) ix) Neuromuscular disease or drugs affecting neuromuscular function x) Androgen therapy in males xi) Estrogen therapy in females xii) Significant immune disorder xiii) Kidney Failure xiv) Pancreatic disease xv) Diabetes xvi) Gastrointestinal or malabsorption diseases xvii) History of cholecystectomy xviii) Use of probiotics, prebiotics or antibiotics in the past 3 months xix) The subject has any other condition, which in the opinion of the Investigator, precludes the subject's participation in the trial.

xx) With the goal of matching the HF and LF groups for age, sex,and BMI, subjects may be excluded because their age, sex or BMI puts them outside the range needed for this study.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02811445). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search